MSJ

Our journals are part of the international community of @ECTRIMS @ACTRIMS @PACTRIMS_admin @lactrims_org and @eurims You can read our articles on: Multiple Sclerosis Journal journals.sagepub.com/home/msj MSJ Experimental Translational and Clinical journals.sagepub.com/home/mso

Estimates of #MultipleSclerosis disability and predictions of its progression using routinely collected healthcare data. Advanced data analytics from @giuseppinaaffi3 @RPalladino84 @UninaIT ▶️ journals.sagepub.com/doi/full/10.11…

🤩 Exciting new study published in @MSJ_Research 💻 See how we significantly enhanced the cognitive outcomes of patients with multiple sclerosis using a non-invasive #telehealth intervention doi.org/10.1177/205521…

From 2020 to 2024, there has been increasing number of pregnancies in women with #MultipleSclerosis being conceived on monoclonal antibody therapies, without overt safety signals. Study from @vjokubaitis @MonashUni @drorlagray @setrust @MSBase_Registry ▶️ journals.sagepub.com/doi/full/10.11…

Real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing #MultipleSclerosis. Delphi panel from @HopkinsMedicine @UTSWMedCenter ▶️ journals.sagepub.com/doi/full/10.11…

New online! Advancing multiple sclerosis management in older adults bit.ly/3IIZRQM

📢July issue is now available ▶️ journals.sagepub.com/toc/MSJ/current ...and the cover goes to @UMontreal @chumontreal @UQAM with their review on subjective cognitive impairment in #MultipleSclerosis ▶️journals.sagepub.com/doi/abs/10.117…

📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠 Register here to receive our research 🔽 journals.sagepub.com/connected/MSJ

Our latest #MSResearch Spotlight focuses on global perspectives on the proposed 2024 McDonald Criteria. #MS experts from Thailand and Chile share real-world insights on applying the criteria across diverse healthcare systems. Read more: bit.ly/4kPn1lE @MahidolU

There is high frequency of co-occurrence of #MultipleSclerosis with several autoimmune diseases, suggesting shared genetic susceptibility factors. A population-based study with genetic linkage from @regionepiemonte ▶️ journals.sagepub.com/doi/full/10.11…

The importance of patient-reported outcomes: A call for their integration in the routine care of patients with #MultipleSclerosis. Review from @drmelcalvert @CPROR_UoB @unibirmingham ▶️ journals.sagepub.com/doi/full/10.11…

Did you publish your first article as first author in 2024 on our journals? Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #MSJ (stay tuned at the #ECTRIMS2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcher… Deadline: TODAY

New issue of Multiple Sclerosis Journal – Experimental, Translational and Clinical is now available online journals.sagepub.com/toc/msoa/11/2 ▶️ and is full open access 🔓

Did you publish your first article as first author in 2024 on our journals? Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #MSJ (stay tuned at the #ECTRIMS2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcher… Deadline: TOMORROW

People with #MultipleSclerosis using disease-modifying therapies have disproportionately high malignant melanoma reporting compared to all other medications. A disproportionality analysis of the @FDA adverse event reporting system @harvardmed ▶️ journals.sagepub.com/doi/abs/10.117…

🔊 Listen to @CagolAlessandr0 @RC2NB @alexrovirarayos @vallhebron: PRLs are reliable across diverse #MultipleSclerosis populations and imaging platforms, reinforcing readiness for real-world application. 📰 And read the editorial ▶️journals.sagepub.com/doi/full/10.11…

Out of 856 people with #MultipleSclerosis, 38.4% had at least one comorbidity (from 24.0% at age 15–29 years to 52.6% at 50–76 years, which was in turn associated with disability. Study from @IsfUniversity @UniSouthDenmark ▶️ journals.sagepub.com/doi/full/10.11…

So it is no, or at least not now.

Did you publish your first article as first author in 2024 on our journals? Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #MSJ (stay tuned at the #ECTRIMS2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcher… Deadline: Jul 19

The benefit of initial high-efficacy treatment for #MultipleSclerosis diminishes with age, but, at individual level, exposure to treatment reduces risks of disability, suggesting prolonged treatment is needed. Real-world study from @UNI_FIRENZE ▶️ journals.sagepub.com/doi/abs/10.117…

Validation studies on the BICAMS in LATAM for cognitive assessment in #MultipleSclerosis, included a greater proportion of relapsing patients and middle-aged adults, thus requiring further evaluations. Review from @udg_oficial ▶️ journals.sagepub.com/doi/full/10.11…